IBL News

Any IBL product introduced in this IBL news is applicable for research use only and it cannot be used for diagnosis or medical purpose.

A research group led by Vistarra Inc. (US) is developing a monoclonal antibody (VIS649) that inhibits a cytokine called APRIL for a treatment of IgA nephropathy and conducted a Phase I trial in 51 healthy adults.
  The study was conducted to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of VIS649 in healthy subjects. In the study, it was reported that VIS649 reduced serum Gd-IgA1.

This is considered a great step toward the treatment of IgA nephropathy.
The pathogenesis of IgA nephropathy is complex, and the "multi-hit theory" is now widely accepted. The multi-hit theory refers to the formation of immune complexes containing Gd-IgA1 through the progression of multiple processes, and IgA nephropathy is developed by deposition in the glomeruli of the kidneys.
Since the increase in the blood level of Gd-IgA1 is one of the multi-hit in this theory, the decrease of Gd-IgA1 level may have the effect of preventing the IgA nephropathy development.

Please refer to the original article below for Phase I study of VIS649.   APRIL is involved in IgA class switching in the mucosa and the maturation of plasma cells, which are thought to be Gd-IgA1-producing cells, and it was reported that the serum level of APRIL correlate with the prognosis of IgA nephropathy. Thus, it is discussed that APRIL might play some roles in IgA nephropathy.

Another anti-monoclonal antibody (BION1301) under developed by Chinook Therapeutics is undergoing Phase I/II trials for IgA nephropathy patients. BION1301 decreased proteinuria and Gd-IgA1.

Atacicept, a TACI-IgG Fc fusion protein that inhibit APRIL and BAFF, was also reported to decrease Gd-IgA1. Furthermore, this drug reduced proteinuria, and maintained renal function of IgA nephropathy patients compared to the placebo.

Please refer to the original article below for Study of Atacicept.
The development of new therapeutic medicine for IgA nephropathy, targeting inhibition of APRIL, is actively progressing.
  IgA nephropathy is the most common primary glomerulonephritis worldwide, with a global prevalence of 2.5 per 100,000 adults per year and is one of the first causes of end-stage renal disease (ESRD). No specific and causative treatment strategies have been developed, and it is estimated that 30-40% of cases lead to ESRD within 10-20 years of onset.

Disease-specific biomarkers with prognostic value and putative therapeutic approaches targeting updated pathogenetic processes are being evaluated in ongoing clinical trials worldwide. Tremendous progress has been made in understanding the disease, there are still a number of questions that require clarification.

Please refer to the original article below for About IgA nephropathy.   our ELISA kit below is used for the measurement of Gd-IgA1. IBL will contribute the development to supply research kits with accurate data.

【Related product】
#10777 Anti-Human Gd-IgA1(KM55) Rat IgG MoAb

We hope that we can support your research.
Please feel free to contact us.

Sales Department
Antibody related Business Division
Immuno-Biological Laboratories Co., Ltd.
Email: do-ibl@ibl-japan.co.jp

IBL-Japan (Specific Antibody Development) 2min video
IBL-Japan (Specific Antibody Development) 30sec video
LipoSEARCH® - Lipoprotein Analyzing Systems (Patented GP-HPLC Systems) 30sec video